Vyvanse Global Regulatory Status

FDA Approval History

The FDA approved lisdexamfetamine dimesylate (Vyvanse) on February 23, 2007, for the treatment of attention-deficit/hyperactivity disorder in children ages 6 through 12, making it the first prodrug stimulant to receive U.S. marketing authorization for ADHD [1]. Shire Pharmaceuticals developed the compound specifically to provide a longer duration of action and a pharmacokinetic profile that would reduce the abuse potential associated with immediate-release amphetamine formulations.

The approval rested on two key phase III trials. A randomized, double-blind, placebo-controlled study of 290 children demonstrated statistically significant improvements on the ADHD Rating Scale IV (ADHD-RS-IV) at doses of 30 mg, 50 mg, and 70 mg compared with placebo (P<0.001 for all doses) [1]. In a laboratory classroom study, lisdexamfetamine produced significant improvement in the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) deportment scores from 1.5 hours through 13 hours post-dose, confirming a full-day efficacy window [2].

The FDA subsequently expanded the indication to include adults with ADHD in 2008. That decision was based on a four-week randomized trial of 420 adults aged 18 to 55, in which lisdexamfetamine (30, 50, or 70 mg/day) separated from placebo on the ADHD-RS-IV with adult prompts at all three dose levels [3].

A second therapeutic indication arrived in January 2015, when the FDA approved Vyvanse for moderate-to-severe binge eating disorder in adults. This made lisdexamfetamine the first (and, as of 2026, still the only) medication with specific FDA approval for BED [4]. The BED approval drew on two identically designed 12-week trials (Study 1: N=383; Study 2: N=390) in which 50 mg and 70 mg doses significantly reduced binge eating days per week versus placebo [4].

Controlled Substance Classification

Lisdexamfetamine is classified as a Schedule II controlled substance under the U.S. Controlled Substances Act (CSA). This is the most restrictive category for substances with accepted medical use. Schedule II status requires written prescriptions (no phone-in or fax orders in most states), limits on refills (none permitted; a new prescription is needed each time), and strict production quotas set annually by the DEA [5].

The Schedule II designation matches the classification applied to other amphetamine-based medications, including mixed amphetamine salts (Adderall) and dextroamphetamine (Dexedrine). Takeda's original NDA submission emphasized the prodrug mechanism, arguing that lisdexamfetamine's requirement for enzymatic cleavage in the bloodstream would attenuate the rewarding effects of intranasal or intravenous misuse. A human abuse liability study showed that intranasal lisdexamfetamine produced significantly lower "drug liking" scores than equivalent doses of immediate-release d-amphetamine (P<0.05), though the FDA determined the abuse potential remained high enough to warrant Schedule II placement rather than the less restrictive Schedule III or IV [6].

International scheduling varies by jurisdiction but follows a broadly similar pattern. Canada lists lisdexamfetamine under Schedule III of the Controlled Drugs and Substances Act. Australia classifies it as a Schedule 8 (controlled drug). The United Kingdom placed it in Schedule 2 of the Misuse of Drugs Regulations 2001. Japan approved lisdexamfetamine (marketed as Vyvanse) in 2019 for pediatric ADHD, classifying it as a stimulant controlled under the Stimulants Control Act [7].

European and International Regulatory Pathways

Unlike many centrally authorized medicines, lisdexamfetamine did not receive a single European Medicines Agency (EMA) marketing authorization through the centralized procedure. Instead, Shire pursued national-level approvals across individual EU member states through mutual recognition and decentralized procedures. This approach reflected the regulatory complexity of scheduling a controlled stimulant across countries with differing national drug control frameworks.

By 2026, lisdexamfetamine holds marketing authorizations in over 40 countries. The geographic spread spans North America (United States, Canada), Europe (United Kingdom, Germany, France, Spain, Ireland, Sweden, Denmark, and others), Asia-Pacific (Japan, South Korea, Australia), and Latin America (Brazil, Mexico). Each jurisdiction applies its own controlled substance restrictions and, in several cases, limits the approved indications. Japan, for example, approved lisdexamfetamine only for pediatric ADHD (ages 6 to 17) and has not added an adult ADHD or BED indication [7]. Brazil's ANVISA approved the drug for ADHD in both children and adults but has not authorized the BED indication.

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) monitors post-market safety data across EU member states through periodic safety update reports (PSURs). A 2020 PRAC review of all centrally and nationally authorized ADHD stimulants, including methylphenidate and lisdexamfetamine, concluded that the known cardiovascular and psychiatric risks were adequately reflected in existing product information and did not require new regulatory action [8].

Current Label: Indications, Dosing, and Warnings

The U.S. prescribing information (PI) for Vyvanse, maintained in the Drugs@FDA database, specifies two approved indications: ADHD in patients aged 6 years and older, and moderate-to-severe BED in adults aged 18 and older [9]. The label explicitly states that Vyvanse is "not indicated for weight loss," a distinction regulators added to prevent off-label marketing for obesity.

Recommended starting doses differ by indication and age. For ADHD in patients 6 and older, the recommended starting dose is 30 mg once daily in the morning, titrated in increments of 10 mg or 20 mg at approximately weekly intervals, with a maximum recommended dose of 70 mg/day. For BED in adults, the recommended starting dose is also 30 mg/day, titrated to a target dose of 50 to 70 mg/day [9].

The boxed warning addresses two risks common to all Schedule II stimulants. First, high potential for abuse and dependence: amphetamines have been extensively abused, and the label warns that misuse may cause sudden death and serious cardiovascular adverse events. Second, the warning notes that prolonged use may lead to drug dependence, and that administration should be for the shortest duration consistent with treatment goals. The label carries additional warnings for serious cardiovascular events (sudden death in patients with pre-existing structural cardiac abnormalities, stroke, myocardial infarction), blood pressure and heart rate increases, psychiatric adverse events (psychosis, mania, aggression), long-term growth suppression in pediatric patients, and peripheral vasculopathy including Raynaud's phenomenon [9].

A Medication Guide is required to be dispensed with each prescription, and a Risk Evaluation and Mitigation Strategy (REMS) was not mandated, though Takeda participates in the class-wide ADHD stimulant REMS involving the Medication Guide distribution [9].

Post-Market Surveillance and Safety Signals

The FDA monitors lisdexamfetamine through multiple post-market channels. The FDA Adverse Event Reporting System (FAERS) collects spontaneous reports from healthcare professionals and patients. The FDA Sentinel System, a distributed data network covering over 100 million patients in claims databases, enables active surveillance queries on specific safety questions without relying solely on voluntary reporting [10].

Cardiovascular safety has been the most scrutinized area. A large retrospective cohort study using administrative claims data (N=43,999 lisdexamfetamine users matched to 175,955 non-users) found no statistically significant increase in the composite risk of stroke, myocardial infarction, or sudden cardiac death among adult ADHD stimulant users (adjusted hazard ratio 0.83, 95% CI 0.72 to 0.96) [11]. This aligns with the broader literature on stimulant cardiovascular safety, though the FDA has maintained the boxed warning on the grounds that rare events in vulnerable subpopulations remain a concern.

Growth suppression in children is another area of ongoing monitoring. Wigal et al. (2017) published the longest prospective safety analysis of lisdexamfetamine, following 314 children for up to 5 years. The study found that height and weight z-scores decreased during the first 1 to 2 years of treatment but stabilized or showed partial recovery by years 3 through 5. Mean height z-score change from baseline was -0.34 at year 2 and -0.23 at year 5, suggesting initial growth attenuation followed by a compensatory rebound [2]. The label recommends monitoring height and weight at baseline and periodically during treatment, with consideration of treatment interruption in children who are not growing or gaining weight as expected [9].

Misuse and diversion patterns represent a third surveillance priority. A 2019 analysis of the National Survey on Drug Use and Health (NSDUH) estimated that prescription stimulant misuse affected approximately 5.1 million Americans aged 12 and older in the preceding year. Lisdexamfetamine accounted for a smaller share of stimulant-related emergency department visits than immediate-release amphetamine formulations, consistent with its prodrug pharmacology limiting the peak plasma concentration achievable through non-oral routes [12].

Generic Entry and Patent Expiration

Vyvanse's U.S. patent exclusivity expired in August 2023, and several generic lisdexamfetamine dimesylate products entered the market shortly thereafter. Manufacturers including Teva, Amneal, Alvogen, and others received ANDA approvals from the FDA. Generic availability reduced average out-of-pocket costs substantially. Prior to generic entry, a 30-day supply of brand-name Vyvanse carried a wholesale acquisition cost (WAC) exceeding $400; generic versions were priced at roughly 60% to 70% lower at launch [13].

The FDA's Orange Book lists Vyvanse with a therapeutic equivalence rating of AB for the capsule formulations, confirming that approved generics are considered bioequivalent and therapeutically interchangeable. The chewable tablet formulation also has approved generics with AB ratings [13]. Takeda retains the brand-name product on the market but has seen predictable market share erosion consistent with typical Schedule II stimulant generic entry patterns.

In Europe, generic lisdexamfetamine approvals are proceeding on a country-by-country basis, with timelines influenced by national patent law, supplementary protection certificates (SPCs), and data exclusivity periods. Several EU member states granted generic marketing authorizations in 2024 and 2025 [8].

Regulatory Comparisons with Other ADHD Stimulants

Lisdexamfetamine occupies a distinct regulatory position among ADHD medications. It is the only prodrug amphetamine with FDA approval, and the only stimulant of any class approved specifically for BED. Methylphenidate (Ritalin, Concerta), the other major ADHD stimulant class, shares the Schedule II classification but lacks BED approval. Non-stimulant options such as atomoxetine (Strattera), viloxazine (Qelbree), and guanfacine (Intuniv) carry no controlled substance scheduling.

The Endocrine Society and the American Psychiatric Association do not issue joint guidelines on ADHD pharmacotherapy, but the American Academy of Pediatrics (AAP) 2019 clinical practice guideline recommends FDA-approved stimulants, including lisdexamfetamine, as first-line pharmacotherapy for ADHD in children aged 6 and older, noting "strong" evidence quality [14]. The guideline does not express a preference between amphetamine-class and methylphenidate-class stimulants, leaving the choice to clinician judgment and patient response.

For BED specifically, the American Psychiatric Association's 2023 practice guideline identifies lisdexamfetamine as the medication with the strongest evidence base, reflecting its status as the only FDA-approved pharmacotherapy for the condition [15].

Ongoing Regulatory Developments

Several regulatory developments are expected to affect lisdexamfetamine's status in the coming years. The FDA's 2024 proposed rulemaking on stimulant telehealth prescribing, prompted by pandemic-era flexibilities under the Ryan Haight Act, could alter how lisdexamfetamine is prescribed through telemedicine platforms. As a Schedule II substance, lisdexamfetamine requires an in-person evaluation under pre-pandemic DEA rules. The DEA's final rule on post-pandemic telehealth prescribing of controlled substances, expected in 2026, will determine whether audio-video evaluations remain sufficient for initial Schedule II prescriptions [16].

Takeda has not publicly disclosed plans for new indication submissions. Academic interest exists in lisdexamfetamine for treatment-resistant depression augmentation and cognitive dysfunction in various conditions, but no phase III registration-directed trials for these indications have been announced as of May 2026. Any new indication would require a supplemental NDA (sNDA) with the FDA and separate submissions to other national regulatory agencies.

The FDA Sentinel System's active monitoring of ADHD stimulants continues under the Sentinel routine querying program, with annual updates on cardiovascular and psychiatric safety signals across the stimulant class [10]. Clinicians prescribing lisdexamfetamine should check the FDA's MedWatch page and the Drugs@FDA label repository for the most current safety communications.